GlassScriptPhysician profile
Shubi Shahida
NPI 1407803562
$12,458.28
in general payments reported to CMS, 2019-2025
56 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,445 · 2020: $863 · 2021: $1,726 · 2022: $1,784 · 2023: $2,171 · 2024: $2,372 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,455 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,455.17 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,831.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,788.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,013.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $857.73 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $830.45 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $674.48 | 2019-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $649.06 | 2019-2024 | Seglentis, Livalo, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.61 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $447.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $329.07 | 2022-2025 | |
| Pfizer INC. | $298.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $297.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.98 | 2019-2023 | Jardiance, Synjardy, Glyxambi |
| Paratek Pharmaceuticals, INC. | $258.64 | 2021-2025 | Nuzyra, Xhance |
| Astellas Pharma US INC | $220.95 | 2024-2025 | Veozah |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shubi Shahida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.